WindMIL Therapeutics is Drug Discovery in United States that focus on T-cells that business. Founded in 2015. They cover business area such as developer, oncology cell therapy, novel insight, bone marrow immunology, life-save cell therapy, cancer patient, re-activate t-cell, leverage bone marrow-derive lymphocyte, immunotherapy, healthcare professional, cancer cell therapy.
2015
( 9 years old in 2024 )
T-cells That
-
1812 Ashland Avenue
Suite 100
Baltimore, MD 21205
United States
Private
developeroncology cell therapynovel insightbone marrow immunologylife-save cell therapycancer patientre-activate t-cellleverage bone marrow-derive lymphocyteimmunotherapyhealthcare professionalcancer cell therapy
* We use standard office opening hours in near WindMIL Therapeutics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
WindMIL Therapeutics is Drug Discovery business from United States that founded in 2015 (9 years old in 2024), WindMIL Therapeutics business is focusing on T-cells That.
WindMIL Therapeutics headquarter office and corporate office address is located in 1812 Ashland Avenue Suite 100 Baltimore, MD 21205 United States.
WindMIL Therapeutics was founded in United States.
In 2024, WindMIL Therapeutics is currently focus on T-cells that sector.
Above is snippet of Google Trends for "T-cells that" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with WindMIL Therapeutics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
